Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR
...ll present results of two preclinical studies with sapacitabine and seliciclib, the company's most advanced drug c...geles Convention Center between April 14-18, 2007. sapacitabine is an orally-available, novel nucleoside analog in...pment in patients with non-small cell lung cancer. sapacitabine and seliciclib are the lead drug candidates in Cyc...Sapacitabine - Wikipedia, the free encyclopedia
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine ... Retrieved from "http://en.wikipedia.org /wiki/ Sapacitabine" ...CYCC Cyclacel Begins Phase 2 Study of Oral Sapacitabine in Patients ...
TradingMarkets News for CYCC - Cyclacel Begins Phase 2 Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung CancerCYCC Cyclacel Reports Phase 2 Sapacitabine Data in Patients With Acute ...
TradingMarkets News for CYCC - Cyclacel Reports Phase 2 Sapacitabine Data in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes At 2009 ASCO Annual ...News: Cyclacel Expands Phase 2 Sapacitabine Trial in Elderly AML to ...
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced that it has advanced sapacitabine into Phase 2 development as a second-line treatment for ...Methods of treatment using sapacitabine
Further aspects of the invention relate to kits directed to the same. ... Sapacitabine, also known as 1-(2-C-cyano-2-deoxy-β-DCyclacel Expands Phase 2 Sapacitabine Trial In Elderly AML To ...
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced that it has advanced sapacitabine into Phase 2 development as a second-line treatment for ...